We found similar trends between a transient increase in serum CA19-9, CRP, YKL-40, and IL-6 and a good prognosis, as with the serum CEA, raising the question of whether a transient increase in a serum biomarker level during chemotherapy could be associated with a favourable survival in other types of human cancer. The gene discussed is CEACAM5; the disease is cancer.